Medicinal chemistry strategies of targeting HIV-1 capsid protein for antiviral treatment

Future Medicinal ChemistryVol. 12, No. 14 EditorialMedicinal chemistry strategies of targeting HIV-1 capsid protein for antiviral treatmentShujing Xu, Lin Sun, Boshi Huang, Xinyong Liu & Peng ZhanShujing XuDepartment of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Shandong University, 44 West Culture Road, 250012 Jinan, Shandong, PR China, Lin SunDepartment of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Shandong University, 44 West Culture Road, 250012 Jinan, Shandong, PR China, Boshi HuangDepartment of Medicinal Chemistry, School of Pharmacy, Virginia Commonwealth University, 800 E Leigh Street, Richmond, VA 23298, USA, Xinyong LiuDepartment of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Shandong University, 44 West Culture Road, 250012 Jinan, Shandong, PR China & Peng Zhan*Authors for correspondence: E-mail Address: zhanpeng1982@sdu.edu.cnDepartment of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Shandong University, 44 West Culture Road, 250012 Jinan, Shandong, PR ChinaPublished Online:2 Jun 2020https://doi.org/10.4155/fmc-2020-0084AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleKeywords: CA inhibitordrug designmedicinal chemistry strategyReferences1. Carnes SK, Sheehan JH, Aiken C. Inhibitors of the HIV-1 capsid, a target of opportunity. Curr. Opin. HIV AIDS 13(4), 359–365 (2018).Crossref, Medline, CAS, Google Scholar2. Bartonova V, Igonet S, Sticht J et al. Residues in the HIV-1 capsid assembly inhibitor binding site are essential for maintaining the assembly-competent quaternary structure of the capsid protein. J. Biol. Chem. 283(46), 32024–32033 (2008).Crossref, Medline, CAS, Google Scholar3. Sticht J, Humbert M, Findlow S et al. A peptide inhibitor of HIV-1 assembly in vitro. Nat. Struct. Mol. Biol. 12(8), 671–677 (2005).Crossref, Medline, CAS, Google Scholar4. Blair WS, Pickford C, Irving SL et al. HIV capsid is a tractable target for small molecule therapeutic intervention. PLoS Pathog. 6(12), 653–653 (2010).Crossref, Google Scholar5. Lemke CT, Titolo S, von Schwedler U et al. Distinct effects of two HIV-1 capsid assembly inhibitor families that bind the same site within the N-terminal domain of the viral CA protein. J. Virol. 86(12), 6643–6655 (2012).Crossref, Medline, CAS, Google Scholar6. Thenin-Houssier S, de Vera IM, Pedro-Rosa L et al. Ebselen, a small-molecule capsid inhibitor of HIV-1 replication. Antimicrob. Agents Chemother. 60(4), 2195–2208 (2016).Crossref, Medline, CAS, Google Scholar7. Tang C, Loeliger E, Kinde I et al. Antiviral inhibition of the HIV-1 capsid protein. J. Mol. Biol. 327(5), 1013–1020 (2003).Crossref, Medline, CAS, Google Scholar8. Kortagere S, Madani N, Mankowski MK et al. Inhibiting early-stage events in HIV-1 replication by small-molecule targeting of the HIV-1 capsid. J. Virol. 86(16), 8472–8481 (2012).Crossref, Medline, CAS, Google Scholar9. Li F, Goila-Gaur R, Salzwedel K et al. PA-457: a potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing. Proc. Natl Acad. Sci. USA 100(23), 13555–13560 (2003).Crossref, Medline, CAS, Google Scholar10. Xu JP, Francis AC, Meuser ME et al. Exploring modifications of an HIV-1 capsid inhibitor: design, synthesis, and mechanism of action. J. Drug Des. Res. 5(2), 1070 (2018).Medline, Google Scholar11. Fader LD, Bethell R, Bonneau P et al. Discovery of a 1,5-dihydrobenzo[b] [1,4]diazepine-2,4-dione series of inhibitors of HIV-1 capsid assembly. Bioorg. Med. Chem. Lett. 21(1), 398–404 (2011).Crossref, Medline, CAS, Google Scholar12. Tian B, He M, Tang S et al. Synthesis and antiviral activities of novel acylhydrazone derivatives targeting HIV-1 capsid protein. Bioorg. Med. Chem. Lett. 19(8), 2162–2167 (2009).Crossref, Medline, CAS, Google Scholar13. Fader LD, Landry S, Goulet S et al. Optimization of a 1,5-dihydrobenzo[b] [1,4]diazepine-2,4-dione series of HIV capsid assembly inhibitors 2: structure–activity relationships (SAR) of the C3-phenyl moiety. Bioorg. Med. Chem. Lett. 23(11), 3401–3405 (2013).Crossref, Medline, CAS, Google Scholar14. Tremblay M, Bonneau P, Bousquet Y et al. Inhibition of HIV-1 capsid assembly: optimization of the antiviral potency by site selective modifications at N1, C2 and C16 of a 5-(5-furan-2-yl-pyrazol-1-yl)-1H-benzimidazole scaffold. Bioorg. Med. Chem. Lett. 22(24), 7512–7517 (2012).Crossref, Medline, CAS, Google Scholar15. Wang X, Huang B, Liu X, Zhan P. Discovery of bioactive molecules from CuAAC click-chemistry-based combinatorial libraries. Drug Discov. Today 21(1), 118–132 (2016).Crossref, Medline, CAS, Google Scholar16. Wu G, Zalloum WA, Meuser ME et al. Discovery of phenylalanine derivatives as potent HIV-1 capsid inhibitors from click chemistry-based compound library. Eur. J. Med. Chem. 158, 478–492 (2018).Crossref, Medline, CAS, Google Scholar17. Zhang H, Zhao Q, Bhattacharya S et al. A cell-penetrating helical peptide as a potential HIV-1 inhibitor. J. Mol. Biol. 378(3), 565–580 (2008).Crossref, Medline, CAS, Google Scholar18. Garzon MT, Lidon-Moya MC, Barrera FN et al. The dimerization domain of the HIV-1 capsid protein binds a capsid protein-derived peptide: a biophysical characterization. Protein Sci. 13(6), 1512–1523 (2004).Crossref, Medline, CAS, Google Scholar19. Zhang H, Curreli F, Zhang X et al. Antiviral activity of α-helical stapled peptides designed from the HIV-1 capsid dimerization domain. Retrovirology 8(1), 28 (2011).Crossref, Medline, CAS, Google Scholar20. Perrier M, Bertine M, Le Hingrat Q et al. Prevalence of gag mutationsassociated with in vitro resistance to capsid inhibitor GS-CA1 in HIV-1 antiretroviral-naive patients. J. Antimicrob. Chemother. 72(10), 2954–2955 (2017).Crossref, Medline, CAS, Google ScholarFiguresReferencesRelatedDetailsCited ByFrom design to biological mechanism evaluation of phenylalanine-bearing HIV-1 capsid inhibitors targeting a vital assembly interfaceChinese Chemical Letters, Vol. 34, No. 3The discovery and design of novel HIV-1 capsid modulators and future perspectives15 December 2022 | Expert Opinion on Drug Discovery, Vol. 18, No. 1Metabolite Identification of HIV-1 Capsid Modulators PF74 and 11L in Human Liver Microsomes16 August 2022 | Metabolites, Vol. 12, No. 8HIV-1 capsid inhibitors: a sword to destroy the virusXujie Zhang, Shujing Xu, Lin Sun, Dang Ding, Yucen Tao, Dongwei Kang, Xinyong Liu & Peng Zhan17 March 2022 | Future Medicinal Chemistry, Vol. 14, No. 9Design, synthesis, and mechanistic investigations of phenylalanine derivatives containing a benzothiazole moiety as HIV-1 capsid inhibitors with improved metabolic stabilityEuropean Journal of Medicinal Chemistry, Vol. 227Design, synthesis, and antiviral activity of phenylalanine derivatives as HIV-1 capsid inhibitorsBioorganic & Medicinal Chemistry, Vol. 48An insight on medicinal aspects of novel HIV-1 capsid protein inhibitorsEuropean Journal of Medicinal Chemistry, Vol. 217 Vol. 12, No. 14 Follow us on social media for the latest updates Metrics Downloaded 123 times History Received 24 March 2020 Accepted 2 April 2020 Published online 2 June 2020 Published in print July 2020 Information© 2020 Newlands PressKeywordsCA inhibitordrug designmedicinal chemistry strategyFinancial & competing interests disclosureThe financial support from the National Natural Science Foundation of China (NSFC no. 81973181), the Key Project of NSFC for International Cooperation (no. 81420108027), the National Key Projects of New Drugs R&D (no. 2019ZX09301-126), the Key research and development project of Shandong Province (nos. 2017CXGC1401 and 2019JZZY021011) and the Taishan Scholar Program at Shandong Province. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.Writing assistance was utilized in the production of this manuscript.PDF download